- Home
- UGRO vs CANF Comparison
UGRO vs CANF Comparison
Compare UGRO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- CANF
- Stock Information
- Founded
- UGRO 2014
- CANF 1994
- Country
- UGRO United States
- CANF Israel
- Employees
- UGRO N/A
- CANF N/A
- Industry
- UGRO Industrial Specialties
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- CANF Health Care
- Exchange
- UGRO Nasdaq
- CANF Nasdaq
- Market Cap
- UGRO 18.0M
- CANF 14.4M
- IPO Year
- UGRO N/A
- CANF N/A
- Fundamental
- Price
- UGRO $1.40
- CANF $2.27
- Analyst Decision
- UGRO Strong Buy
- CANF Strong Buy
- Analyst Count
- UGRO 2
- CANF 2
- Target Price
- UGRO $5.63
- CANF $14.00
- AVG Volume (30 Days)
- UGRO 21.1K
- CANF 136.1K
- Earning Date
- UGRO 11-07-2024
- CANF 11-15-2024
- Dividend Yield
- UGRO N/A
- CANF N/A
- EPS Growth
- UGRO N/A
- CANF N/A
- EPS
- UGRO N/A
- CANF N/A
- Revenue
- UGRO $70,320,066.00
- CANF $667,000.00
- Revenue This Year
- UGRO $14.76
- CANF $356.93
- Revenue Next Year
- UGRO $21.29
- CANF N/A
- P/E Ratio
- UGRO N/A
- CANF N/A
- Revenue Growth
- UGRO 12.08
- CANF N/A
- 52 Week Low
- UGRO $1.02
- CANF $1.81
- 52 Week High
- UGRO $2.84
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- UGRO 50.90
- CANF 59.89
- Support Level
- UGRO $1.34
- CANF $1.87
- Resistance Level
- UGRO $1.55
- CANF $2.55
- Average True Range (ATR)
- UGRO 0.10
- CANF 0.15
- MACD
- UGRO 0.01
- CANF 0.05
- Stochastic Oscillator
- UGRO 54.55
- CANF 67.19
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).